MAPLIGHT THERAPEUTICS ANNOUNCES COMPLETION OF DOSING IN PHASE 1 STUDY OF THERAPY FOR SOCIAL DEFICIT IN AUTISM SPECTRUM DISORDER
Interim data from Phase 1 clinical trial with repeated dosing in healthy volunteers demonstrates positive safety and tolerability profile for ML-004 SAN FRANCISCO, November 23, 2020 – MapLight Therapeutics today announced it has completed dosing of healthy volunteers across five cohorts in a Phase 1 clinical trial evaluating the safety of ML-004, a selective serotonin … Continued